Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 1;83(6):522-530.
doi: 10.1097/FJC.0000000000001497.

Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure

Ehsan Jafree  1 , Marco Giuseppe Del Buono  2   3 , Justin M Canada  4 , Salvatore Carbone  5 , Jordana Kron  4 , Ross Arena  6 , Benjamin Van Tassell  7 , Antonio Abbate  8 , Cory R Trankle  4
Affiliations
Review

Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure

Ehsan Jafree et al. J Cardiovasc Pharmacol. .

Abstract

Heart failure (HF) is a complex syndrome that remains a leading cause of morbidity and mortality worldwide. Abundant evidence suggests inflammation plays a key role in the development and perpetuation of HF, but there are currently no anti-inflammatory treatments approved for use in HF. Interleukin-1, the prototypical proinflammatory cytokine, has been implicated in adverse cardiac remodeling and left ventricular dysfunction. Multiple early phase clinical trials using interleukin-1 blockade in patients at risk for or diagnosed with HF have suggested favorable safety and efficacy in reducing inflammatory biomarkers, as well as positive signals in surrogate and clinical end points. Additional large scale clinical trials are urgently needed to confirm the safety and efficacy of this therapeutic approach specifically in HF. In this narrative review, we discuss current evidence regarding interleukin-1 blockade in the prevention and treatment of HF.

PubMed Disclaimer

Conflict of interest statement

A. Abbate has served as a consultant for CardiolRx, Implicit Bioscience, Kiniksa, Novo Nordisk, Olatec, R-Pharm, Serpin Pharma, Swedish Orphan Biovitrum. The remaining authors report no conflicts of interest.

Similar articles

See all similar articles

Cited by

References

    1. Del Buono MG, Arena R, Borlaug BA, et al. Exercise Intolerance in Patients With Heart Failure. Journal of the American College of Cardiology. 2019;73(17):2209–2225. doi:10.1016/j.jacc.2019.01.072 - DOI - PubMed
    1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. Published online 2022. doi:10.1016/j.jacc.2021.12.012 - DOI
    1. Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329(10):827. doi:10.1001/jama.2023.2020 - DOI - PubMed
    1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8). doi:10.1161/CIR.0000000000001052 - DOI - PubMed
    1. Elster SK, Braunwald E, Wood HF. A study of C-reactive protein in the serum of patients with congestive heart failure. American Heart Journal. 1956;51(4):533–541. doi:10.1016/0002-8703(56)90099-0 - DOI - PubMed

Publication types

MeSH terms